Cancer Immunotherapy Consortium
The Cancer Immunotherapy Consortium (CIC) is a think tank consisting of industry leaders from the cancer immunotherapy space. The CIC acts as a neutral platform whereby industry representatives work together and align on important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit.
The CIC will convene and address topics of importance to the development of immunotherapies. Outcomes will be available to all stakeholders in the field. Immediate topics to be addressed by the group include immune-related Response Criteria (irRC) and second generation biomarkers.
Evolution of the Program
The CIC was founded in 2002 as an international association of pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and development with the ultimate goal of making cancer immunotherapies part of the standard-of-care in oncology. Following the 2011 FDA approval of ipilimumab (Yervoy®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved. Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a “think tank” that would convene and tackle topics of importance to the continued development of cancer immunotherapies.